The rapid ascent of GLP-1 receptor agonists has transformed the clinical approach to obesity, shifting the focus toward significant weight reduction. However, this pharmacological success has highlighted a critical systemic challenge: the preservation of lean body mass. While the scale shows a decrease in total weight, the composition of that loss is a growing concern for public health officials and clinicians, as the reduction of non-fat components, including skeletal muscle, can undermine the very metabolic benefits these drugs aim to achieve.
The Challenge of Lean Mass Preservation
Lean body mass is a primary driver of basal metabolic rate and is fundamentally linked to long-term metabolic health and a reduced risk of type 2 diabetes. When weight loss occurs too rapidly or without sufficient muscle protection, the resulting loss of lean tissue can lead to diminished physical strength and impaired functionality. Evidence suggests that between 25% and 40% of total weight loss during GLP-1 therapy may be attributed to the loss of lean mass rather than adipose tissue, a ratio that alarms clinicians who are now prescribing these drugs at scale through both specialist clinics and primary care.
Prof Alexander Miras, an obesity expert at Ulster University, notes that while these medications improve overall functionality in terms of daily activities, the loss of muscle mass is a significant trade-off. “This means that [people] may be less able to lift heavy weights, for example, or walk up a hill,” Miras said. “This new medication may help reduce the effects of GLP-1-based drugs on muscle strength and therefore improve functionality even further compared to someone not on the new medication who is just taking tirzepatide.”
Clinical Outcomes of Myostatin Inhibition
To address this imbalance, researchers have investigated the use of apitegromab, a monoclonal antibody designed to block myostatin-a protein that naturally inhibits muscle growth and is already being evaluated for conditions such as spinal muscular atrophy.1 A study published in Nature Medicine examined whether combining this muscle-promoting agent with tirzepatide (the active ingredient in Mounjaro) could decouple weight loss from muscle wasting.
The trial involved 102 participants over a 24-week period, divided equally between a treatment group and a placebo group. All participants received tirzepatide, reflecting how regulators are likely to view any future myostatin blockers not as stand‑alone obesity drugs but as adjuncts to the new generation of incretin-based therapies.
| Metric | Tirzepatide + Placebo | Tirzepatide + Apitegromab |
|---|---|---|
| Total Weight Loss | Similar across both groups | Similar across both groups |
| Average Lean Mass Loss | 3.5kg | 1.6kg |
| Lean Mass Loss (% of total) | Higher baseline loss | 14.6% |
| Lean Mass Retention | Baseline | 55% greater than placebo |
The researchers found that while total weight loss remained consistent across both groups, the addition of apitegromab significantly mitigated the loss of lean tissue. Side effects were reported as mild and occurred at similar rates in both cohorts, a safety profile that will be closely scrutinised by regulators already reviewing apitegromab as a biologic for neuromuscular disease.2
Systemic Implications for Metabolic Health
From a regulatory and public health perspective, the potential for combination therapies marks a shift from focusing solely on body mass index (BMI) to focusing on body composition, including how much weight loss comes from fat versus muscle. That shift is occurring just as agencies such as the U.S. Food and Drug Administration are being asked to weigh not only short‑term efficacy but also long‑term functional outcomes and disability risk in obesity drug approvals.
However, the transition to these high-cost, specialized therapies raises questions regarding healthcare infrastructure and equitable access. The use of monoclonal antibodies alongside GLP-1s increases the economic burden on health systems and payers, potentially widening disparities if insurers restrict coverage to those with severe disease or specific comorbidities. It also demands more rigorous oversight to ensure long-term safety, with payers and regulators likely to insist on post‑marketing surveillance and real‑world evidence on falls, frailty and hospitalisations.
Prof Naveed Sattar, a cardiometabolic medicine expert at the University of Glasgow, emphasizes that the current findings, while promising, are preliminary. “This is an early-stage trial that suggests novel drugs can help mitigate muscle mass loss with prescribed tirzepatide. However, it’s too early to say whether this actually benefits peoples health or ability to move or function better,” he said.
Beyond pharmacological intervention, there is a critical need for integrated care models that combine medication with sustainable lifestyle support. Prof Sattar notes: “In the meantime, people prescribed these drugs should be supported to increase their physical activity, as this can help maintain muscle mass in a physiological way. Importantly, activity should also be framed as something enjoyable and sustainable, rather than purely as a medical add‑on,”
As the pharmaceutical industry moves toward more targeted “muscle-sparing” weight loss cocktails, regulatory bodies will likely require larger-scale, longitudinal trials to determine if lean mass retention translates into meaningful improvements in patient longevity and quality of life. For policymakers and health services, the central question is no longer just how much weight a drug can help patients lose, but whether the next wave of obesity treatments can deliver that loss without sacrificing the muscle needed for healthy ageing, work and independence.
